OREANDA-NEWS. MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:

Commerzbank Sector Conference 2016
Date: August 30, 2016
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG;
Dr. Claudia Gutjahr-L?ser, Head of Corporate Communications & IR
 
Goldman Sachs Annual Biotech Symposium
Date: September 9, 2016
Venue: London, UK
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG;
Dr. Claudia Gutjahr-L?ser, Head of Corporate Communications & IR

Morgan Stanley Global Healthcare Conference
Date: September 12-14, 2016
Venue: New York, NY, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG;
Dr. Claudia Gutjahr-L?ser, Head of Corporate Communications & IR

J.P. Morgan London Small/Mid Cap Conference
Date: September 13, 2016
Venue: London, UK
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG

Bank of America Merrill Lynch Global Healthcare Conference 2016
Date: September 15, 2016, 4:10 pm BST (11:10 am EDT, 5:10 pm CEST)
Venue: London, UK
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG;
Dr. Claudia Gutjahr-L?ser, Head of Corporate Communications & IR

Fifth Berenberg and Goldman Sachs Annual German Corporate Conference
Date: September 20, 2016, 4:30 pm CEST (3:30 pm BST, 10:30 am EDT)
Venue: Munich, Germany
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG;
Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG

Baader Investment Conference
Date: September 22, 2016, 8:00 am CEST (7:00 pm BST, 2:00 am EDT)
Venue: Munich, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG;
Dr. Claudia Gutjahr-L?ser, Head of Corporate Communications & IR

About MorphoSys
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.